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Abstract
Background: once  metastasized,  despite  a  variety  of
therapeutic  options,  the  prognosis  of  patients  with
malignant melanoma (MM) is still poor. Therefore, the
search  for  reliable  markers  to  identify  patients  with
high risk of disease progression is of high clinical im-
portance. we have recently shown that TT genotypes
of the single-nucleotide polymorphism (SNP) T393C
in the gene GNAS1 are significantly associated with
better outcome in a variety of carcinomas.
Patients: In the present study we assessed whether the
T393C  SNP  is  also  related  to  the  clinical  course  in
MM. 328 patients with MM were retrospectively geno-
typed and genotypes were correlated with clinical out-
come.
Results: while the allele frequency in the MM group
(fC  0.52)  did  not  significantly  differ  from  that  of
healthy blood donors, the T393C SNP was associated
with tumor progression of MM. Carriers of the C-al-
lele showed a significantly more severe tumor progres-
sion  as  estimated  from  the  time  period  to  develop
metastasis (HR 2.2, 95% CI 1.1-3.2, p = 0.017). Pro-
portions  of  5-year  metastasis-free  intervals  were
87.1% for TT genotypes and 66.0% for C-allele carri-
ers.  Moreover,  multivariable  Cox  regression  analysis
including tumor stage and melanoma subtype proved
the T393C polymorphism to be an independent factor
for metastasis (p = 0.012).
Conclusions: In  summary,  the  GNAS1 T393C  SNP
represents a genetic host factor for predicting tumor
progression also in patients with MM; genotyping of
this SNP may contribute to better define patients who
could benefit from an early individualized therapy. 
Key words: polymorphism, G Protein, melanoma, pro  -
gnostic factor
INTRodUCTIoN
Early detection of metastasis is one of the aims of
follow-up  examination  in  patients  with  malignant
melanoma since once metastasized, despite a variety of
therapeutic options e. g. chemo- and/ or immunother-
apy, patients suffering from malignant melanoma show
an unfavorable prognosis. Therefore, it would be most
desirable to identify patients with high risk of disease
progression as early as possible [1]. Since laboratory
tests are easy to handle and modestly expensive, a vari-
ety of different serum factors has been investigated
for their potential relevance as prognostic markers in
malignant  melanoma  [2-4].  To  date,  none  of  these
markers is routinely used in the clinical setting. The
most promising one at present, S100-protein, has been
demonstrated in several studies to be a valid and reli-
able predictive marker for clinical progression and re-
sponse to therapy in melanoma patients with advanced
stages of disease [5, 6]. However, a major disadvantage
of S100-protein is its poor prognostic impact in early-
stage melanoma patients [6-8].
The identification of new prognostic markers may
help to better distinguish low from high risk disease
apart  from  the  classical  histopathologic  and  clinical
criteria and may unravel new targets for therapy. The
mechanism of malignant transformation of melano  -
cytes  is  poorly  understood,  but  growth  factors  and
their receptors play an important role in the progres-
sion of melanoma [9]. Moreover, alterations in the mi-
togen-activated protein kinase pathway are almost uni-
formly present in melanoma. while RAS itself is only
infrequently  mutated  in  melanoma  [10]  the  down-
stream BRAF gene of the mitogen activated protein
kinase pathway is mutated in 60% to 70% of superfi-
cial spreading melanomas [11]. on the other hand, a
genetic host factor may offer a better stratification of
patients into more refined risk categories without the
need for tumor tissue. For example, the A61G single
nucleotide  polymorphism  (SNP)  in  the  EGF  gene
which operates via RAS and BRAF in melanocytic tu-
mors has recently been associated with risk for metas-
tasis in melanoma patients [12]. 
we have recently shown that the T393C polymor-
phism in the gene GNAS1, which encodes the G_s
subunit of heterotrimeric G protein, is significantly as-
sociated with the clinical outcome of patients suffer-
ing from bladder cancer [13], colorectal cancer [14],
chronic lymphocytic leukaemia [15], and renal cell car-
cinoma [16]. we also demonstrated that the T allele of
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creased Gas mRNA expression in a variety of tissues,
including tumor tissue [14]. In vitro experiments sug-
gest that an increased expression of Gas is associated
with enhanced apoptosis and that the second messen-
ger  cAMP,  which  functions  downstream  of  G  pro-
teins, plays a major role in this pro-apoptotic process
[17-20].  Hence,  an  increased  Gas  expression  with
concomitantly enhanced apoptosis may be also associ-
ated  with  better  survival  in  melanoma  patients  with
TT genotypes. 
MATERIAlS ANd METHodS
PATIENTS
This study comprises a total of 328 consecutive malig-
nant melanoma patients (with a mean age of 54.2 ﾱ
16.4 years) treated at the department of dermatology
and  Allergology,  Ruhr-University  Bochum  (Bochum,
Germany) between 1995 and 2000 with disease pro-
gression being continuously documented. The clinical
staging  was  performed  according  to  the  American
Joint  Committee  on  Cancer  (AJCC  1997).  Briefly,
stages  I  and  II  included  patients  with  primary
melanoma,  stage  III  included  patients  with  regional
lymph node and/or in-transit metastases and stage IV
included  patients  with  distant  metastases.  Patients
were  treated  according  to  therapy  protocols  of  the
dermatologic  Cooperative  oncology  Group
(deCoG) including cytostatic drugs (dacarbacine, cis-
platinum,  temozolomide,  vincristine)  and  im-
munomodulatory agents [interferon(IFN)] in different
combinations  and  schedules.  Follow-up  was  per-
formed in at least 3-months intervals including physi-
cal examination, x-ray of the chest, ultra- sound of the
abdomen and lymph nodes as well as blood chemistry.
Patients in advanced disease stages additionally under-
went computer tomography of the brain and szintigra-
phy of the skeleton. detailed clinical characteristics of
the study patients are summarized in Table 1. The ret-
rospective  analysis  and  genotyping  of  dNA  from
paraffin-embedded tissues in an anonymous form was
approved by the ethical committee of the University
Hospital Essen (Essen, Germany).
GENoTyPING
dNA  was  extracted  from  paraffin-embedded  tissue
samples using a commercially available kit (QIAAmp,
Qiagen, Hilden, Germany). Genotypes of the T393C
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Table 1.
All TT TC CC P
N (%) 328 69 (21.0) 149 (45.4) 110 (33.5)
Gender (m/f) 167/161 30/39 86/63 51/59 0.074
Mean age at diagnosis  54.2 55.0 54.4 53.4 0.517
UICC Category.
I 202 (61.6) 45 (22.3) 85 (42.1) 72 (35.6)
II 72 (22.0) 13 (18.1) 34 (47.2) 25 (34.7)
III 47 (14.3) 9 (19.1) 30 (63.8) 8 (17.0)
IV 7 (2.1) 2 (28.6) 0 (0) 5 (71.4) 0.683
Type
SSM 153 31 71 51
NM 38 8 16 14
lMM 34 9 14 11
AlM 30 7 16 7
UCM 73 14 32 27
Tumor thickness (mm)
<0,75 191 (58.2) 40 (20.9) 80 (41.9) 71 (37.2)
0,75-1,5 55 (16.8) 14 (25.5) 27 (49.1) 14 (25.5)
1,5- 4 58 (17.7) 8 (13.8) 31 (53.4) 19 (32.8)
>4 24 (7.3) 7 (29.2) 11 (45.8) 6 (25.0) 0.385
Clark level
I 51 (15.5) 10 (19.6) 22 (43.1) 19 (37.3)
II 40 (12.2) 10 (25.0) 15 (37.5) 15 (37.5)
III 114 (34.8) 24 (21.1) 50 (43.9) 40 (35.1)
IV 92 (28.0) 20 (21.7) 45 (48.9) 27 (29.1)
V 10 (3.0) 2 (20.0) 6 (60.0) 2 (20.0) 0.333
Node
0 305 (93.0) 66 (21.6) 135 (44.3) 104 (34.1)
1 13 (4.0) 3 (23.1) 6 (46.2) 4 (30.8)
2 10 (3.0) 0 (0) 8 (80.0) 2 (20.0) 0.865
distant metastasis
No 321 (97.9) 67 (20.9) 149 (46.4) 105 (32.7)
yes 7 (2.1) 2 (28.6) 0 (0,0) 5 (71.4) 0.266
M; male; f, female; SSM, superficial spreading melanoma; NM, nodular melanoma; lMM, lentigo maligna melanoma; AlM,
acral lentiginous melanoma; UCM, unclassified melanoma
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lowing primers: forward primer 5ﾴ-CTCCTAACTGA
CATGGTGCAA-3ﾴ and reverse primer 5ﾴ-TAAGGC
CACACAAGTCGGGGT-3ﾴ.  After  denaturation  at
94ﾰC,  35  cycles  of  dNA  amplification  were  per-
formed using Taq PCR Mastermix (Eppendorf, Ham-
burg, Germany) at 94ﾰ for 45 sec, 58ﾰC for 40 sec-
onds, and 72ﾰ for 45 seconds. The 345 bp PCR prod-
ucts were digested using the restriction enzyme FokI
and analyzed on a 2% agarose gel. The unrestricted
products (345 bp) represented the TT genotype; the
completely restricted products (259 and 86 bp) repre-
sented the CC genotype.
STATISTICAl ANAlySIS
The clinical outcome analyzed in this study was sur-
vival,  and  metastasis  dependent  on  UICC  stages,
melanoma  subtypes,  and  T393C  genotypes.  Kaplan-
Meier plots and the log-rank test were used to evaluate
the relationship between UICC stages, melanoma sub-
types or T393C genotypes, and clinical outcome from
the date of the primary diagnosis to the end of fol-
low-up. The effects of gender, age at diagnosis, UICC
stages, and T393C genotypes as prognostic factors for
the clinical outcome were analyzed by stepwise multi-
variate Cox regression analysis. Hazard ratios and 95%
confidence  intervals  (95%  CI)  were  calculated  from
the Cox regression model including all factors for mul-
tivariate analysis and for the indicated factor for uni-
variate analysis. Contingency tables and the Pearson’s
chi-square test were used for categorical variables us-
ing T393C genotypes. linear ANoVA was used for
comparison of continuous variables where appropri-
ate. differences were regarded significant at P < 0.05.
All  statistical  analyses  were  done  using  SPSS  13.0
(SPSS, Chicago, Il) or GraphPad Prism 4.0 (Graph-
Pad Software, San diego, CA). Continuous variables
are given as means ﾱ Sd or ﾱ SE as indicated. 
RESUlTS
GENoTyPE dISTRIBUTIoN
demographic  characteristics  and  tumor  stage  in  the
whole patient group and by T393C genotypes are dis-
played in Table 1. The frequency of the C allele in the
patient group was 0.52 and genotype distribution was
compatible  with  the  Hardy-weinberg  equilibrium.
Genotypes and allele frequency of patients were com-
parable with those of healthy white blood donors; de-
tails of this control group have been published previ-
ously  [21].  This  argues  against  an  association  of
T393C genotypes with an increased susceptibility for
malignant melanoma. we found no genotype associa-
tion  with  age  at  time  of  first  diagnosis.  Moreover,
genotypes were not significantly associated with tumor
localization,  UICC  classification,  or  tumor  thickness
(Table 1).
T393C GENoTyPE ANd ClINICAl Follow UP
during  follow  up,  85  patients  (25.9%)  experienced
metastases and 88 (28.1%) died. In order to confirm
that our sample was representative for patients with
malignant  melanoma  we  calculated  Kaplan-Meier
curves  for  overall  survival  depending  on  the  UICC
stages and tumor subtype. As shown in Fig. 1 A-B,
overall  survival  was  significantly  dependent  upon
AJCC stage and tumor type. Five-year survival rates
were 90.4% for UICC I, 77.1% for UICC II, 52.4%
for UICC III, and 28.6% for UICC IV. Regarding tu-
mor types, 5-year survival rates were 83.4% for SSM,
73.3% for NM, 87.3% for lMM, 75.0% for AlM and
79.4% for UCM. These findings are comparable with
those from the literature [22].
Concerning genotypes of the T393C polymorphism
we  observed  no  association  with  overall  survival.
However,  we  detected  a  significant  allele-dependent
influence upon tumor progression. GNAS1 393C al-
lele carriers displayed a higher risk for metastasis (C
versus TT: 2.2, 95% CI 1.1-3.2, p = 0.017) compared
to T393 homozygous patients. Proportions of 5-year
metastasis free intervals were 87.1% for TT genotypes
and 66.0% for C-allele carriers, respectively (Fig. 2).
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Fig,  1. Kaplan-Meier curves for overall survival in 328 pa-
tients with malignant melanoma based on the UICC stage (A)
and tumor subtype (B). SSM, superficial spreading melanoma;
NM, nodular melanoma; lMM, lentigo maligna melanoma;
AlM,  acral  lentiginous  melanoma;  UCM,  unclassified
melanoma. 
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agnosis,  tumor  stage,  and  melanoma  subtype,  the
T393C polymorphism was an independent marker for
tumor progression. The hazard ratio for patients with
C-alleles was 2.55 for metastasis compared to homozy-
gous 393T allele carriers (Table 2).
dISCUSSIoN
Although  UICC  stages  generally  correlate  with  out-
come in a large percentage of cancer patients, refined
prediction of the individual disease course would facil-
itate clinical decision making, e.g. early requirement of
adjuvant  therapy.  The  familial  melanoma  syndromes
are associated with germ line mutations in three highly
penetrant gene products: p16, alternate reading frame,
and  cyclin-dependent  kinase  4.  Certain  variants  in  a
low-penetrance gene, MC1R, the melanocortin 1 re-
ceptor gene, increase melanoma risk to a lesser extent
and act as genetic modifiers when cosegregating with a
deleterious p16 gene [23]. Since the immune response
against malignant melanoma cells can be influenced by
cytokines with potentially inhibitory effects on tumor
cell growth, SNPs in cytokine genes associated with
reduced cytokine production are expected to influence
susceptibilityto cancer, including malignant melanoma.
Genotypes  associated  with  reduced  production  of
pro-inflammatory  and  immunomodulatory  TNF-al-
pha, IFN-gamma, and Il-6, and anti-inflammatory Il-
10 and TGF-beta1 could be involved in mechanisms
of cancer progression and escape from immunosur-
veillance [24]. Genotypic variations in the Il10 pro-
motor  are  significantly  associated  with  an  increased
risk for malignant melanoma and may be associated
with a poor outcome [25]. one of the aims of the pre-
sent study was, therefore, to investigate whether the
common  T393C  SNP  in  the  gene  GNAS1,  may  be
predictive for survival or disease-free survival in pa-
tients with malignant melanoma. 
The mean age of the patients of the present malig-
nant melanoma series was 54.2 years and the median
follow-up time was 80 months. distribution of tumor
stage and subtype of the whole series were compatible
with  data  reported  in  the  literature.  Results  of  the
German  Central  Register  of  Malignant  Melanoma
showed a mean age of 58.1 year and a similar distribu-
tion of subtypes as reported here [26]. Beside the role
of tumor stage and tumor thickness as the most im-
portant  prognostic  factor  in  patients  with  malignant
melanoma, our data suggest a potential predictive use
of the GNAS1 T393C SNP as an independent prog-
nostic factor in malignant melanoma. C-allele carriers
have  an  increased  risk  for  tumor  progression  when
compared  to  patients  with  the  homozygous  393TT
genotype, the latter group showing both a longer re-
lapse-free  survival  and  a  later  requirement  for  sec-
ondary therapy. Together with our previous observa-
tions  showing  that  the  T393C  SNP  is  a  predictive
marker for outcome in bladder cancer [13], renal cell
carcinoma [16] and colorectal cancer [14], the present
results confirm the potential role of this SNP as a uni-
versal  genetic  marker  for  predicting  tumor  progres-
sion. The GNAS1 TT genotype is associated with in-
creased Gas mRNA expression in different tissues14
which led us to hypothesize that the T393C exchange
itself could have an effect upon mRNA stability. Inter-
estingly,  determinants  of  mRNA  stability  have  been
described in the coding region of some other genes
[27-29]. different in vitro experiments suggest that in-
creased  expression  of  Gas  is  associated  with  en-
hanced  apoptosis  [17-19].  The  second  messenger
cyclic AMP, which is generated subsequently to activa-
tion of Gas, seems to play a major role in this pro-
apoptotic process. Cyclic AMP can augment or sup-
press ERK activity, depending on the cell type. As an
example,  CRAF  is  inhibited  by  protein  kinase  A,
which is one of the downstream effectors of cAMP
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Fig. 2. Kaplan-Meier curves for metastasis-free survival in 328
patients with malignant melanoma based on T393C alleles.
Table  2.  Multivariable  Cox  proportional  hazard  model  for
metastasis in 328 patients with malignant melanoma.
Metastasis
Hazard ratio 95% CI p
Age at diagnosis 1.0 0.98-1.02 0.802
Gender
Male 1*
Female 0.96 0.61 - 1.53 0.866
UICC Stage
I 1*
II 1.91 0.96 - 3.81 0.067
III 12.19 6.30 - 23.56 <0.001
IV 21.47 6.03 - 76.49 <0.001
MM Type
SSM  1*
NM 1.89 0.92 - 3.88 0.081
lMM 2.75 1.14 - 6.2 0.024
AlM 1.56 0.74 - 3.33 0.239
UCM 2.38 1.23 - 4.58 0.010
T393C
TT 1*
C 2.55 1.22 - 5.32 0.012
*reference group. CI, confidence interval. SSM were chosen
as reference because they represent the largest subgroup of
melanomas.  SSM,  superficial  spreading  melanoma;  NM,
nodular melanoma; lMM, lentigo maligna melanoma; AlM,
acral lentiginous melanoma; UCM, unclassified melanoma
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cytic agonists such as a-melanocyte-stimulating hor-
mone acting through the melanocortin 1 receptor [31]
resulting in activation of Gas. Although this is only
able to weakly stimulate proliferation, cAMP is closely
associated with melanocyte differentiation (e. g. stimu-
lation of melanin synthesis) [32]. 
A  recent  report  has  shown  that  cAMP  blocks
CRAF activity in melanocytes resulting in suppression
of the oncogenic activity of CRAF in these cells [33].
This process could be of particular importance in TT
genotypes in which Gas expression is increased. How-
ever, CRAF is not required for MEK/ERK signalling
in  melanoma  cells  when  BRAF  is  mutated  [34,  35].
late  mutations  in  the  BRAF  gene  could,  therefore,
mitigate the T393C genotype effect which may explain
the lack of genotype-dependent differences in overall
survival. This hypothesis is supported by observations
from  studies  in  different  types  of  cancer  in  which
BRAF mutations are rarely events and in which then
the T393C SNP affects overall survival [36]. The goal
of ongoing studies is to unravel both the detailed mol-
ecular  mechanisms  by  which  the  silent  C393T  SNP
contributes to differential Gas expression in human
tissues and how this may change the phenotype of dif-
ferent tumor cells.
The authors state no conflict of interest.
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